PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsMidas Pharma
Midas Pharma
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
RanivisioRanibizumab2022-08-25
Diabetes complications
,
Macular edema
,
Retinal vein occlusion
,
Diabetic retinopathy
,
Wet macular degeneration
,
Choroidal neovascularization
,
Degenerative myopia
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Angiotensin ii
healthy volunteers/patients
,
hypertrophic cardiomyopathy
,
cardiomyopathies
,
headache
,
cluster headache
,
diabetic retinopathy
,
breast neoplasms
,
hyperkalemia
,
migraine disorders
,
migraine without aura
,
migraine with aura
,
aortic valve stenosis
,
pathologic constriction
,
cardiotoxicity
,
retinal diseases
,
proteinuria
,
atrial fibrillation
,
stroke
,
chronic renal insufficiency
,
renal insufficiency
,
hypertension
,
heart failure
,
type 2 diabetes mellitus
,
diabetes mellitus
,
type 1 diabetes mellitus
,
hypertrophy
,
obesity
,
kidney diseases
,
left ventricular dysfunction
,
ventricular dysfunction
,
left ventricular hypertrophy
,
glucose intolerance
,
cohort studies
,
essential hypertension
,
diabetic nephropathies
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use